newsfilter
← Latest News
GlobeNewswire·

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of